A 23-year-old male has been experiencing hair loss since 2022 and has used minoxidil and dutasteride with reduced shedding but no hair regrowth. He is considering PRP with mesotherapy and red light therapy, GFC, or exosomes, with a preference for exosomes due to efficiency and a reputable clinic.
A user improved their hair health by taking 50,000 IU of vitamin D3 weekly due to a deficiency. Others discussed the potential link between vitamin D and hair growth, with some sharing similar experiences and emphasizing the importance of monitoring vitamin D levels and consulting with doctors.
PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.
Minoxidil may cause wrinkles and dark circles, which some users report can be mitigated by adjusting dosage. Reactions vary, and while some dismiss these side effects, others experience significant changes.
The user shared their hair loss treatment progress using topical products like exosomes, fluridil, Kx826, and topical dutasteride, avoiding oral finasteride and dutasteride due to side effects. They found exosomes from Creative Biolabs most effective and also used topical probiotics, noting improvements without significant side effects.
Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.
The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.
Pyrilutamide (KX826) sourcing and pricing, with users discussing the legitimacy and cost of grey market versus official sources. The conversation highlights the high cost of official products and the effectiveness of grey market versions.
The user successfully managed hair regrowth by using a combination of finasteride, dutasteride, minoxidil, and specific shampoos to treat seborrheic dermatitis. They emphasize the importance of maintaining a healthy scalp and are considering food intolerance tests to further address inflammation.
Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.
A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.
The user reported slight improvement in hairline using 1% Clascoterone cream over three months but found it too costly to continue. They expressed interest in trying a 5% concentration if it becomes available at a reasonable price.
Exosomes were used for hair loss treatment, showing results 33 days after the second session. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.
The conversation discusses treating male pattern baldness in a transgender woman using cyproterone acetate, finasteride, and biotin. The original poster shared their experience for others who might be in a similar situation.
PP405 may not need daily use like minoxidil, but finasteride might still be needed to maintain hair regrowth. PP405 reawakens dormant hair follicles, potentially offering a long-term solution, though not a permanent cure.
Oral supplementation of Nicotinamide Mononucleotide (NMN) improves hair quality and appearance in middle-aged women. However, it may reduce total hair density, possibly due to seasonal shedding.
The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.
The user reports improvement in temple hair after three weeks of using finasteride, minoxidil, ketoconazole, microneedling, stemoxydine, and follicopeptide. They note visible progress by maintaining the same hair length for comparison.
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.
The conversation discusses a video about hair shedding related to finasteride and dutasteride, with some users debating the credibility of non-professional sources. The video is praised for compiling work by doctors and researchers, despite some users preferring content from licensed medical professionals.
Age-linked hair loss is linked to disappearing collagen. Treatments discussed include minoxidil, finasteride, RU58841, tretinoin, microneedling, and collagen supplements.
Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.
PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.